Cite
HARVARD Citation
Voorhees, P. et al. (n.d.). A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. British journal of haematology. pp. 357-366. [Online].